167 related articles for article (PubMed ID: 19733005)
1. Targeting the 90 kDa heat shock protein improves photodynamic therapy.
Ferrario A; Gomer CJ
Cancer Lett; 2010 Mar; 289(2):188-94. PubMed ID: 19733005
[TBL] [Abstract][Full Text] [Related]
2. Survivin, a member of the inhibitor of apoptosis family, is induced by photodynamic therapy and is a target for improving treatment response.
Ferrario A; Rucker N; Wong S; Luna M; Gomer CJ
Cancer Res; 2007 May; 67(10):4989-95. PubMed ID: 17510430
[TBL] [Abstract][Full Text] [Related]
3. Pro-apoptotic and anti-inflammatory properties of the green tea constituent epigallocatechin gallate increase photodynamic therapy responsiveness.
Ferrario A; Luna M; Rucker N; Wong S; Gomer CJ
Lasers Surg Med; 2011 Sep; 43(7):644-50. PubMed ID: 22057492
[TBL] [Abstract][Full Text] [Related]
4. Effects of HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin (17-AAG) on NEU/HER2 overexpressing mammary tumours in MMTV-NEU-NT mice monitored by Magnetic Resonance Spectroscopy.
Rodrigues LM; Chung YL; Al Saffar NM; Sharp SY; Jackson LE; Banerji U; Stubbs M; Leach MO; Griffiths JR; Workman P
BMC Res Notes; 2012 May; 5():250. PubMed ID: 22621282
[TBL] [Abstract][Full Text] [Related]
5. Induction of prosurvival molecules during treatment: rethinking therapy options for photodynamic therapy.
Gomer CJ
J Natl Compr Canc Netw; 2012 Oct; 10 Suppl 2():S35-9. PubMed ID: 23055213
[TBL] [Abstract][Full Text] [Related]
6. Heat Shock Protein 90 Inhibitor Decreases Collagen Synthesis of Keloid Fibroblasts and Attenuates the Extracellular Matrix on the Keloid Spheroid Model.
Lee WJ; Lee JH; Ahn HM; Song SY; Kim YO; Lew DH; Yun CO
Plast Reconstr Surg; 2015 Sep; 136(3):328e-337e. PubMed ID: 26313837
[TBL] [Abstract][Full Text] [Related]
7. 17-AAG inhibits vemurafenib-associated MAP kinase activation and is synergistic with cellular immunotherapy in a murine melanoma model.
Joshi SS; Jiang S; Unni E; Goding SR; Fan T; Antony PA; Hornyak TJ
PLoS One; 2018; 13(2):e0191264. PubMed ID: 29481571
[TBL] [Abstract][Full Text] [Related]
8. Antiangiogenic treatment enhances photodynamic therapy responsiveness in a mouse mammary carcinoma.
Ferrario A; von Tiehl KF; Rucker N; Schwarz MA; Gill PS; Gomer CJ
Cancer Res; 2000 Aug; 60(15):4066-9. PubMed ID: 10945611
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of heat shock protein 90 impairs epidermal growth factor-mediated signaling in gastric cancer cells and reduces tumor growth and vascularization in vivo.
Lang SA; Klein D; Moser C; Gaumann A; Glockzin G; Dahlke MH; Dietmaier W; Bolder U; Schlitt HJ; Geissler EK; Stoeltzing O
Mol Cancer Ther; 2007 Mar; 6(3):1123-32. PubMed ID: 17363505
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of heat shock protein 90 function by 17-allylamino-17-demethoxy-geldanamycin in Hodgkin's lymphoma cells down-regulates Akt kinase, dephosphorylates extracellular signal-regulated kinase, and induces cell cycle arrest and cell death.
Georgakis GV; Li Y; Rassidakis GZ; Martinez-Valdez H; Medeiros LJ; Younes A
Clin Cancer Res; 2006 Jan; 12(2):584-90. PubMed ID: 16428504
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic effects of radiolabeled 17-allylamino-17-demethoxygeldanamycin on human H460 nonsmall-cell lung carcinoma xenografts in mice.
Sun J; Liu L; Jiang X; Chen D; Huang Y
Cancer Biother Radiopharm; 2010 Apr; 25(2):155-64. PubMed ID: 20423228
[TBL] [Abstract][Full Text] [Related]
12. 17-AAG improves cognitive process and increases heat shock protein response in a model lesion with Aβ25-35.
Ortega L; Calvillo M; Luna F; Pérez-Severiano F; Rubio-Osornio M; Guevara J; Limón ID
Neuropeptides; 2014 Aug; 48(4):221-32. PubMed ID: 24819277
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of Hsp90 attenuates inflammation in endotoxin-induced uveitis.
Poulaki V; Iliaki E; Mitsiades N; Mitsiades CS; Paulus YN; Bula DV; Gragoudas ES; Miller JW
FASEB J; 2007 Jul; 21(9):2113-23. PubMed ID: 17400913
[TBL] [Abstract][Full Text] [Related]
14. FLT3 expressing leukemias are selectively sensitive to inhibitors of the molecular chaperone heat shock protein 90 through destabilization of signal transduction-associated kinases.
Yao Q; Nishiuchi R; Li Q; Kumar AR; Hudson WA; Kersey JH
Clin Cancer Res; 2003 Oct; 9(12):4483-93. PubMed ID: 14555522
[TBL] [Abstract][Full Text] [Related]
15. Abrogation of heat shock protein 70 induction as a strategy to increase antileukemia activity of heat shock protein 90 inhibitor 17-allylamino-demethoxy geldanamycin.
Guo F; Rocha K; Bali P; Pranpat M; Fiskus W; Boyapalle S; Kumaraswamy S; Balasis M; Greedy B; Armitage ES; Lawrence N; Bhalla K
Cancer Res; 2005 Nov; 65(22):10536-44. PubMed ID: 16288046
[TBL] [Abstract][Full Text] [Related]
16. Celecoxib and NS-398 enhance photodynamic therapy by increasing in vitro apoptosis and decreasing in vivo inflammatory and angiogenic factors.
Ferrario A; Fisher AM; Rucker N; Gomer CJ
Cancer Res; 2005 Oct; 65(20):9473-8. PubMed ID: 16230411
[TBL] [Abstract][Full Text] [Related]
17. Hsp90 is expressed and represents a therapeutic target in human oesophageal cancer using the inhibitor 17-allylamino-17-demethoxygeldanamycin.
Wu X; Wanders A; Wardega P; Tinge B; Gedda L; Bergstrom S; Sooman L; Gullbo J; Bergqvist M; Hesselius P; Lennartsson J; Ekman S
Br J Cancer; 2009 Jan; 100(2):334-43. PubMed ID: 19142186
[TBL] [Abstract][Full Text] [Related]
18. Modulation of Hsp90 function in neurodegenerative disorders: a molecular-targeted therapy against disease-causing protein.
Waza M; Adachi H; Katsuno M; Minamiyama M; Tanaka F; Doyu M; Sobue G
J Mol Med (Berl); 2006 Aug; 84(8):635-46. PubMed ID: 16741751
[TBL] [Abstract][Full Text] [Related]
19. Dimeric ansamycins--a new class of antitumor Hsp90 modulators with prolonged inhibitory activity.
Zhang H; Yang YC; Zhang L; Fan J; Chung D; Choi D; Grecko R; Timony G; Karjian P; Boehm M; Burrows F
Int J Cancer; 2007 Feb; 120(4):918-26. PubMed ID: 17131314
[TBL] [Abstract][Full Text] [Related]
20. Targeted cancer therapy through 17-DMAG as an Hsp90 inhibitor: Overview and current state of the art.
Mellatyar H; Talaei S; Pilehvar-Soltanahmadi Y; Barzegar A; Akbarzadeh A; Shahabi A; Barekati-Mowahed M; Zarghami N
Biomed Pharmacother; 2018 Jun; 102():608-617. PubMed ID: 29602128
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
